KLRB1 and prostate adenocarcinoma: Previous research has illustrated that high CD161 expression was associated with favorable clinical outcomes across 39 malignancies, including BC, non-small cell lung cancer, prostate adenocarcinoma, cholangiocarcinoma, and mesothelioma etc. (Braud et al., 2018; Zhou et al., 2021; Duurland et al., 2022).